Merck To Use Morphosys' HuCAL Gold Antibodies in Vaccine Research

Aug 05, 2011

Premium

German biotech firm Morphosys said this week its diagnostic antibody unit AbD Serotec has amended its existing license agreement with Merck to include use of its HuCAL Gold technology for vaccine research.

The agreement grants Merck access to the company's HuCAL Gold antibody library for research purposes, as well as the option to upgrade to Morphosys's HuCAL Platinum library.

AbD Serotec will receive annual user fees from Merck for access to the HuCAL technology and license fees for clinical monitoring reagents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Breaking News

The Scan

This Week in PNAS

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

Leaving It All Over Town

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

Balance of Research and Privacy

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

What We'd Do With the Money

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

Featured White Papers

Reverse Phase Protein Arrays for Cell Signaling: Using the InnoScan 710-IR scanner improves sensitivity and dynamic range.

Infrared detection decreases nitrocellulose autofluorescence and improves RPPA assays signal‐to‐noise ratio over visible wavelength detection

Mar

05

Featured Webinar

Integrating Metabolomic and Proteomic Profiles for 'Less Impersonal' Medicine

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.

Main menu